Ignite Creation Date:
2025-12-24 @ 6:47 PM
Ignite Modification Date:
2026-02-20 @ 10:10 PM
Study NCT ID:
NCT02130557
Status:
COMPLETED
Last Update Posted:
2021-05-18
First Post:
2014-05-01
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Sponsor:
Pfizer
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Leukemia | View |
| None | Myelogenous | View |
| None | Chronic | View |
| None | BCR-ABL Positive | View |
| None | Bosutinib | View |
| None | Leukemia, Myeloid | View |
| None | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | View |
| None | Philadelphia Chromosome | View |
| None | Neoplasms by Histologic Type | View |
| None | Bone Marrow Diseases | View |
| None | Hematologic Diseases | View |
| None | Translocation, Genetic | View |
| None | Pathologic Processes | View |
| None | Imatinib | View |
| None | Therapeutic Uses | View |
| None | Pharmacologic Actions | View |
| None | Molecular Mechanisms of Pharmacological Action | View |